Time to enhance COVID-19 vaccination in women of reproductive age

Previous evidence, including major works from the Intercovid multinational consortium, showed that COVID-19 in pregnancy is associated with adverse maternal and neonatal outcomes such as hypertensive disorders, preterm birth (particularly with iatrogenic aetiology), gestational diabetes, foetal distress and reduced foetal growth.1–4 In contrast, pregnant women with complete or boosted vaccination status showed reduced risks of severe morbidity and complications compared to unvaccinated, underscoring the importance of vaccination coverage.5 Two studies from the same consortium, published in The Lancet Regional Health – Europe, reinforce the importance of COVID-19 vaccination in reducing risks of adverse outcomes, including stillbirth and preterm birth